Cover Image

Low tumor interleukin-1β expression predicts a limited effect of adjuvant platinum-based chemotherapy for patients with completely resected lung adenocarcinoma: an identification and validation study

Show other versions (1)

Adjuvant platinum-based chemotherapy for completely resected non-small cell lung cancer is associated with modest improvement in survival; nevertheless, no validated biomarker exists for predicting the benefit or harm of adjuvant platinum-based chemotherapy. We simultaneously measured 27 cytokines i...

Full description

Saved in:
Bibliographic Details
Main Authors: Safi, Seyer (Author) , Krzykalla, Julia (Author) , Hoffmann, Hans (Author) , Benner, Axel (Author) , Bischoff, Helge (Author) , Eichhorn, Martin E. (Author) , Kriegsmann, Mark (Author) , Poschke, Isabel (Author) , Stögbauer, Fabian (Author) , Umansky, Ludmila (Author) , Mogler, Carolin (Author) , Weichert, Wilko (Author) , Winter, Hauke (Author) , Beckhove, Philipp (Author) , Muley, Thomas (Author)
Format: Article (Journal)
Language:English
Published: 24 Oct 2024
In: Pulmonology
Year: 2025, Volume: 31, Issue: 1, Pages: 1-11
ISSN:2531-0437
DOI:10.1016/j.pulmoe.2024.03.003
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1016/j.pulmoe.2024.03.003
Verlag, kostenfrei, Volltext: https://www.tandfonline.com/doi/full/10.1016/j.pulmoe.2024.03.003
Get full text
Author Notes:S. Safi, J. Krzykalla, H. Hoffmann, A. Benner, H. Bischoff, M. Eichhorn, M. Kriegsmann, I. Poschke, F. Stögbauer, L. Umansky, C. Mogler, W. Weichert, H. Winter, P. Beckhove & T. Muley
Description
Summary:Adjuvant platinum-based chemotherapy for completely resected non-small cell lung cancer is associated with modest improvement in survival; nevertheless, no validated biomarker exists for predicting the benefit or harm of adjuvant platinum-based chemotherapy. We simultaneously measured 27 cytokines in operative tumor specimens from a discovery cohort (n = 97) by multiplex immunoassay; half of the patients received adjuvant platinum-based chemotherapy, and the other half were observed. We tested possible prognostic and predictive factors in multivariate Cox models for overall survival (OS) and relapse-free survival (RFS), and a tree-based method was applied to detect predictive factors with respect to RFS. The results were validated in an independent validation cohort (n = 93). Fifty-two of 97 (54 %) patients in the discovery cohort and 50 of 93 (54 %) in the validation cohort received adjuvant chemotherapy; forty-four (85 %) patients in the discovery cohort and 37 (74 %) in the validation cohort received four cycles as planned. In patients with low IL-1β-expressing tumors, RFS and OS were worse after adjuvant chemotherapy than after observation. The limited effect of adjuvant chemotherapy for patients with low IL-1β-expressing tumors was confirmed in the validation cohort. Additionally, RFS and OS were prolonged by adjuvant chemotherapy only in patients with high IL-1β-expressing tumors in the validation cohort. This study identified and validated low tumor IL-1β expression as a potential biomarker of a limited response to adjuvant platinum-based chemotherapy after complete resection of pulmonary adenocarcinoma. This finding has the potential to inform adjuvant treatment decisions.
Item Description:Gesehen am 06.08.2025
Physical Description:Online Resource
ISSN:2531-0437
DOI:10.1016/j.pulmoe.2024.03.003

Similar Items